Description

MK-677 Pellets (Ibutamoren Mesylate)

MK-677, also known as Ibutamoren Mesylate, is a potent, orally active growth hormone secretagogue that mimics the action of ghrelin. It stimulates the release of growth hormone (GH) and increases insulin-like growth factor 1 (IGF-1) levels without affecting cortisol levels. This compound is widely utilized in research settings to explore its potential therapeutic applications in conditions such as growth hormone deficiency, muscle wasting, and osteoporosis.

Product Features and Specifications

Chemical Formula: C27H36N4O5S.CH4O3S
Molecular Weight: 624.77 g/mol
Form: White to off-white pellets, ensuring controlled release and stability.
Purity: ≥99% as determined by HPLC analysis.
Solubility: Soluble in DMSO, ethanol, and other organic solvents.
Storage Conditions: Store at -20°C in a dry, light-protected environment to maintain stability.

Applications

MK-677 Pellets are suitable for various research areas, including:

Growth Hormone Deficiency: Investigating potential therapeutic effects on GH release and IGF-1 levels.
Muscle Wasting Disorders: Studying the impact on muscle mass and strength.
Osteoporosis Research: Exploring effects on bone density and turnover.
Metabolic Studies: Assessing influence on body composition and metabolism.

Research Insights

MK-677 has been extensively studied, with several key findings:

Growth Hormone Secretion: MK-677 has been shown to sustain activation of the GH–IGF-1 axis, increasing growth hormone secretion by up to 97%.
Wikipedia
Lean Body Mass: Studies indicate that MK-677 increases lean body mass with no change in total fat mass or visceral fat.
Bone Mineral Density: Research suggests that MK-677 increases bone mineral density, making it a promising potential therapy for the treatment of frailty in the elderly.
Muscle Mass in Older Adults: MK-677 has been found to increase muscle mass in the arms and legs of older adults, indicating its potential as an anti-frailty agent.

These findings highlight MK-677’s potential in various therapeutic areas, making it a valuable tool for scientific research.

Chemist’s view

MK-677, chemically known as Ibutamoren Mesylate, is a groundbreaking compound in the class of growth hormone secretagogues. From a chemist’s perspective, its structural design and mode of action offer significant insights into the manipulation of endocrine pathways for therapeutic and research applications. As a non-peptidic agonist of the ghrelin receptor (GHSR1a), MK-677 distinguishes itself by its ability to promote the secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) without disrupting cortisol homeostasis, a frequent limitation in similar compounds.

Structurally, MK-677 exhibits high receptor-binding specificity due to its finely tuned hydrophobic and polar functional groups. Its mesylate salt form further enhances its solubility and bioavailability, making it an ideal candidate for oral administration and controlled-release formats such as pellets. This structural optimization ensures a sustained activation of the GH–IGF-1 axis, with measurable effects on both anabolic and metabolic processes over extended periods.

A notable characteristic of MK-677 is its long half-life, approximately 24 hours, which simplifies dosing regimens in research studies. This pharmacokinetic profile reduces the variability often seen with peptide-based secretagogues, as MK-677 resists degradation in the gastrointestinal tract and systemic circulation. Its oral bioavailability and receptor-targeting precision minimize off-target interactions, a critical factor when investigating its therapeutic potential.

In the laboratory, MK-677 is indispensable for exploring the interplay between growth hormone regulation and physiological outcomes such as muscle hypertrophy, enhanced bone density, and fat metabolism. Preclinical studies reveal its ability to increase lean body mass and improve bone mineral density by upregulating osteoblast activity and reducing bone resorption rates. These findings align with its potential applications in addressing conditions such as frailty, sarcopenia, and osteoporosis.

Handling and Safety

Intended Use: For research purposes only. Not for human or veterinary use.
Safety Precautions: Handle with appropriate laboratory safety protocols. Use personal protective equipment to prevent accidental exposure.
Documentation: Material Safety Data Sheet (MSDS) available upon request for detailed safety and handling guidelines.

Packaging Options

Available in 5 mg, 10 mg, and 50 mg pellet formulations.
Custom packaging and bulk quantities are available upon request to meet specific research needs.

Technical Support

Our team offers comprehensive technical assistance for the application and handling of MK-677 Pellets. Contact us for protocol optimization, analytical support, and troubleshooting to ensure successful research outcomes.

MK677 Ibutamoren uk

CAS : CAS 841205-47-8

Supplied in : 10mg Pellet x 90

Specification : ≥ 99.36%

MK677 Ibutamoren Technical Data

Application	A potent, non-peptide ghrelin receptor agonist
Concentration	2,5% (25mg/ml)
Composition	10% ethanol, 87.5% deionized water, 2.5% MK-677 (>98% purity)
CAS	159752-10-0
Molar Mass	528.662 g/mol
Chemical Formula	C₂₇H₃₆N₄O₅S
Synonyms	Ibutamoren, MK-677, MK-0677, L-163,191, L163191, Nutrobal
Storage	Minimize open air exposure, store in a cool dry place
Reports	Click Here
Terms	For research purposes only

Compound Summary – Ibutamoren MK-677

MK-677, also known as Ibutamoren, acts as a non-peptide agonist of the ghrelin receptor and functions as a growth hormone secretagogue, imitating the growth hormone (GH)-stimulating effects of the endogenous hormone ghrelin. This compound is currently being explored for potential applications in treating conditions such as growth hormone deficiency, muscle wasting, and osteoporosis. We will now explore the pharmacological profile, mechanism of action, clinical implications, and safety concerns associated with MK-677 in a thorough and informative manner, reminiscent of the style of Louis S. Goodman:

Pharmacological Profile:

Chemical Nature: MK-677 is classified among growth hormone secretagogues (GHS), which are compounds that promote the release of growth hormone by the pituitary gland.

Mechanism of Action:

GH Secretion: By binding to and activating the ghrelin receptor (GHS-R1a), MK-677 triggers the pituitary gland to release growth hormone, thereby elevating plasma levels of GH and insulin-like growth factor 1 (IGF-1).
Circadian Rhythm: The drug helps maintain a normal circadian rhythm for natural growth hormone spikes, thus replicating the body’s physiological patterns.

Clinical Applications:

Growth Hormone Deficiency: MK-677 can assist in normalizing growth hormone levels in individuals with growth hormone deficiency, impacting growth, body composition, and metabolic processes.
Muscle Wasting and Sarcopenia: The compound’s ability to increase lean body mass suggests potential benefits for treating sarcopenia and muscle wasting related to diseases or aging.
Bone Density: The increase in bone turnover markers indicates potential advantages for bone health, especially beneficial in osteoporosis.

Clinical Studies and Results:

Efficacy in Elderly Patients: Research indicates notable increases in muscle mass and bone mineral density among elderly individuals, showcasing its potential in addressing frailty and osteoporosis.
Long-Term Treatment: Longitudinal studies demonstrate sustained increases in GH and IGF-1 levels with ongoing MK-677 usage.

Side Effects and Safety Profile:

Common Adverse Effects: These include an increase in appetite, mild transient peripheral edema, and muscle pain. Elevated fasting blood glucose levels and decreased insulin sensitivity have also been reported.
Cancer Concerns: Given its role in stimulating GH and IGF-1, which can enhance cell proliferation, there is a theoretical risk in using MK-677 in cancer patients.

Pharmacokinetics:

Administration: MK-677 is taken orally, offering a significant advantage over traditional GH injections.
Absorption and Distribution: The drug is highly bioavailable and reaches peak plasma concentrations within a few hours after ingestion.

Regulatory Status and Considerations:

FDA Approval: MK-677 has not yet been approved by the FDA for any specific condition and is currently restricted to clinical trials and research contexts.
Ethical and Legal Issues: Concerns about potential off-label use, particularly in areas such as performance enhancement and bodybuilding, remain prominent.

References for Further Reading:

“The Ghrelin Receptor: A Novel Prospective Therapy for Growth Hormone Deficiency” by researchers in Endocrinology – provides insights into the role of ghrelin receptor agonists like MK-677 in medical treatment.
“Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial” published in the American Journal of Physiology – discusses the effects of MK-677 on body composition and physical performance in older adults.

MK677 Clinical Safety & Research

Safety Profile of MK-677:
Effects on Cardiovascular: The raised GH levels due to MK-677 can increase fluid retention, which ultimately precipitates peripheral swelling and, possibly, congestive cardiac failure. So it’s more of a concern in patients who have already been having pre-existing heart disease.

Metabolic Concerns: As already alluded to above, MK-677 has been shown to increase fasting blood glucose and decrease insulin sensitivity. This therefore predisposes users to the risk of deteriorating preexisting metabolic conditions such as type 2 diabetes or suffering from new onset diabetes.
Appetite: Since it acts as a ghrelin receptor agonist, the effect on appetite is high, and users find themselves consuming more food than they should. The drug, therefore, cannot be considered safe for administration to an obese or overweight patient.
Cancer Risk: Since GH and IGF-1 have the potential to promote proliferation and inhibit apoptosis, a theoretical risk exists regarding MK-677’s potential to stimulate cancer cell growth. This detail is quite critical to the patient with pre-existed cases of malignancies or those that hold a higher potential of developing cancer.
Hormonal Changes: The effects on GH and Ij-V1 levels may interfere with other hormonal pathways and bring about side effects in the form of increased cortisol, which may interfere with mood, sleep, and immune function.

Clinical trials have generally revealed that MK-677 is able to safely increase the levels of GH with only minor, transient side effects such as joint pain and muscle pain. These findings are very important for the consideration of the therapeutic window and usefulness of conditions like sarcopenia or growth hormone deficiency.

References

Chapman, I. M., et al. (1996). “The effects of human GH and IGF-I on protein metabolism in adults with GH deficiency.” Journal of Endocrinology, focused on GH and IGF-I’s metabolic effects. Available at: Journal of Endocrinology
Adunsky, A., & Chandler, J. (2000). “MK-677: An oral growth hormone secretagogue in older adults with hip fracture.” Journal of the American Geriatrics Society, examined the therapeutic effects and safety of MK-677 in elderly patients. Available at: Journal of the American Geriatrics Society
Nass, R., et al. (2008). “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial.” Annals of Internal Medicine, studied the impact of MK-677 on body composition. Available at: Annals of Internal Medicine
Murphy, M. G., et al. (1998). “MK-677, an oral growth hormone secretagogue, reverses diet-induced catabolism.” Journal of Clinical Endocrinology & Metabolism, detailed the metabolic effects of MK-677. Available at: Journal of Clinical Endocrinology & Metabolism

MK-677 Testing Methods

HPLC

High-performance liquid chromatography

HPLC proves to be a milestone in pharmacological research because it provides such a potent and accurate technique for the separation of chemical compounds from a mixture. In the case of MK677, it is one way to assess purity and stability of the said compound.

This depends on the principle of the differential partitioning between the stationary and mobile phases, allowing effective separation of MK-677 from impurities and degradation products.

Therefore, the current study is focused on the critical evaluation of these critical parameters, such as retention time and peak symmetry, for the integrity and consistency of the compound, which is paramount for the further pharmacological evaluations of the same.

UV-Vis Spectroscopy

Ultraviolet-Visible Spectroscopy (UV-VIS)

UV-VIS spectrophotometric measures are used to measure the absorbance of ultraviolet-visible light by MK677 to provide important electronic structure information and dynamical conformation information.

This method is indispensable in determining the concentration of the compound in a solution and has much use in dosage formulation and kinetic studies. This is achievable through quantification of light amount absorbed by MK-677 at certain wavelengths. The purity and stability of the drug thus allow the researcher to derive accurate pharmacokinetic and pharmacodynamic assessment.

MK-677 (Ibutamoren) / 100 x 10mg